Ensysce Biosciences Inc Ordinary Shares ENSC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
-
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
-
Ensysce Biosciences Reports First Quarter 2026 Financial Results
-
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
-
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
Trading Information
- Previous Close Price
- $0.29
- Day Range
- $0.28–0.29
- 52-Week Range
- $0.24–2.74
- Bid/Ask
- $0.28 / $0.29
- Shares Outstanding
- 15.37M
- Market Cap
- $4.46M
- Volume/Avg
- 46,907 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.ensysce.com
Valuation
|
Metric
|
ENSC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ENSC
|
|---|---|
Quick Ratio | 0.26 |
Current Ratio | 0.71 |
Interest Coverage | −624.84 |
Quick Ratio
ENSC
Profitability
|
Metric
|
ENSC
|
|---|---|
Return on Assets (Normalized) | −252.71% |
Return on Equity (Normalized) | −552.43% |
Return on Invested Capital (Normalized) | −552.66% |
Return on Assets
ENSC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@J&>rvz | LOCK|XjHnl | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|G!TRmP | LOCK|h<XW^ | $71B | |||
| argenx SE ADR
ARGX
| LOCK|D#bMLk | LOCK|!#t | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Yk%NkL | LOCK|t! | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|ZX<hvz | LOCK|RQ?G | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|XbX#G## | LOCK|MPtm | $26B | |||
| Moderna Inc
MRNA
| LOCK|k!?#FS | LOCK|j! | $25B | |||
| Incyte Corp
INCY
| LOCK|Y&r>@! | LOCK|@# | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|@C!sHD | LOCK|NXp | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|w$xQ<> | LOCK|k?m | $16B |
United States